Prognostic value of CpG island methylator phenotype among colorectal cancer patients: A systematic review and meta-analysis

Annals of Oncology

Volumn 25, Issue 12, 2014, Pages 2314-2327

  Juo, Y Y ^a   Johnston, F M ^b   Zhang, D Y ^c   Juo, H H ^d   Wang, H ^a   Pappou, E P ^a   Yu, T ^c   Easwaran, H ^a   Baylin, S ^a,e   van Engeland, M ^f   Ahuja, Nita ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d DANBURY HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adjuvant chemotherapy; CIMP; Colorectal cancer; Epigenetics; Prognosis; Tumor marker

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DISEASE FREE SURVIVAL; DNA METHYLATION; HUMAN; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; COLORECTAL TUMOR; GENETICS; META ANALYSIS; PATHOLOGY; PROGNOSIS;

COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; HUMANS; PHENOTYPE; PROGNOSIS;

EID: 84984879041     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu149     Document Type: Review

References (53)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054.
3. Toyota M, Ho C, Ahuja N et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 2307-2312.
4. Herman JG, Umar A, Polyak K et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870-6875.
5. Shen L, Catalano PJ, Benson AB, III et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007; 13: 6093-6098.
6. Ahn JB, Chung WB, Maeda O et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 2011; 117: 1847-1854.
7. Barault L, Charon-Barra C, Jooste V et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68: 8541-8546.
8. Dahlin AM, Palmqvist R, Henriksson ML et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010; 16: 1845-1855.
9. Ward RL, Cheong K, Ku SL et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003; 21: 3729-3736.
10. Lee S, Cho NY, Choi M et al. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008; 58: 104-113.
11. Ogino S, Nosho K, Kirkner GJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96.
12. Sakamoto E, Tsukioka S, Oie S et al. Folylpolyglutamate synthase and gammaglutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun 2008; 365: 801-807.
13. Kawakami K, Ruszkiewicz A, Bennett G et al. The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 2003; 9: 5860-5865.
14. Raghunathan K, Priest DG. Modulation of fluorouracil antitumor activity by folic acid in a murine model system. Biochem Pharmacol 1999; 58: 835-839.
15. van Rijnsoever M, Elsaleh H, Joseph D et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9: 2898-2903.
16. Jover R, Nguyen TP, Perez-Carbonell L et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011; 140: 1174-1181.
17. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003; 14: 1026-1038.
18. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
19. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
21. Mahesh KB, Parmar VT, Stewart L. Extracting summary statistics to perform metaanalysis of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
22. van Rijnsoever M, Grieu F, Elsaleh H et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002; 51: 797-802.
23. Kim SH, Park KH, Shin SJ et al. Association between CpG island methylator phenotype (CIMP) and treatment response of FOLFIRI with cetuximab in patients with metastatic colorectal cancer (MCRC). Ann Oncol 2012; 23: xi41-xxi2.
24. Benson AB, III, Bekaii-Saab T, Chan E et al. Localized colon cancer, version 3. J Natl Compr Canc Netw 2013; 11: 519-528.
25. Des Guetz G, Schischmanoff O, Nicolas P et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009; 45: 1890-1896.
26. Kim JC, Choi JS, Roh SA et al. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol 2010; 17: 1767-1776.
27. Cushman-Vokoun AM, Stover DG, Zhao Z et al. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. Clin Colorectal Cancer 2013; 12: 168-178.
28. Kakar S, Deng G, Smyrk TC et al. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma. Mod Pathol 2012; 25: 1040-1047.
29. Kim JH, Shin SH, Kwon HJ et al. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009; 455: 485-494.
30. Sanchez JA, Krumroy L, Plummer S et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg 2009; 96: 1196-1204.
31. Min BH, Bae JM, Lee EJ et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011; 11: 344.
32. Zanutto S, Pizzamiglio S, Lampis A et al. Methylation status in patients with early stage colon cancer: a new prognostic marker? Int J Cancer 2012; 130: 488-489.
33. Ogino S, Meyerhardt JA, Kawasaki T et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007; 450: 529-537.
34. Hughes LA, Khalid-de Bakker CA, Smits KM et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta 2012; 1825: 77-85.
35. Kim NJ, Kang KJ, Min BH et al. Sa1579 The role of CpG island methylator phenotype on survival outcome in colon cancer. Gastrointest Endosc 2011; 73: AB213-ABAB4.
36. Suppiah A, Alabi A, Madden L et al. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int J Colorectal Dis 2008; 23: 595-600.
37. Kakar S, Deng G, Sahai V et al. Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. Arch Pathol Lab Med 2008; 132: 958-964.
38. Elsaleh H. Gender, tumor phenotype along with DNA methylation predict survival benefit from 5-fluorouracil in colorectal cancer. A biological basis for chemosensitivity? Cancer J 2003; 9: 496.
39. Rhee YY, Kim MJ, Bae JM et al. Clinical outcomes of patients with microsatelliteunstable colorectal carcinomas depend on L1 methylation level. Ann Surg Oncol 2012; 19: 3441-3448.
40. Altman DG, McShane LM, Sauerbreu W et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216.
41. Ju HX, An B, Okamoto Y et al. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am J Pathol 2011; 178: 1835-1846.
42. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793.
43. Donada M, Bonin S, Barbazza R et al. Management of stage II colon cancer-the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol 2013; 13: 36.
44. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-6069.
45. Al-Sohaily S, Henderson C, Currey N et al. Prognostic value of methylation markers in rectal cancer. Australian Gastroenterology Week 2011 Brisbane, Qld 2011.
46. Jo P, Jung K, Grade M et al. CpG island methylator phenotype infers a poor diseasefree survival in locally advanced rectal cancer. Surgery 2012; 151: 564-570.
47. Samowitz WS, Curtin K, Wolff RK et al. Microsatellite instability and survival in rectal cancer. Cancer Causes Control 2009; 20: 1763-1768.
48. Han SW, Lee HJ, Bae JM et al. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer 2013; 132: 2209-2216.
49. Koo DH, Hong YS, Kim K et al. CpG island methylator phenotype and KRAS mutation status as prognostic markers in patients with resected colorectal cancer. J Clin Oncol 2011; 29(suppl); abstr 3595.
50. Simons CC, Hughes LA, Smits KM et al. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann Oncol 2013; 24: 2048-2056.
51. Kalady MF, Sanchez JA, Manilich E et al. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum 2009; 52: 1039-1045.
52. Zlobec I, Bihl MP, Foerster A et al. Stratification and prognostic relevance of Jass's molecular classification of colorectal cancer. Front Oncol 2012; 2: 7.
53. Jo P, Jung K, Grade M et al. CpG island methylator phenotype infers a poor prognosis in locally advanced rectal cancer. Surgery 2012; 151: 564-570.